Cue Biopharma is trading 5.16% down at $23.34, with the broader biotech sector’s decline potentially contributing; no confirmed company-specific announcement explains the October 13 move. - XBI is down 2.01%, while broader market indexes are nearly flat. - A B. Riley Buy-rating initiation appeared in coverage, but available results do not establish it as a cause of the decline.